PhD, Laboratory Head at the Pharmaco-Neuroimaging and Cognitive-Emotional Processing Research Group in University of Zurich, Visiting Assistant Professor at Yale University
Psychedelic substances are currently being investigated for the treatment of a range of neuropsychiatric illnesses. However, the clinical mechanisms of action still remain unclear. This talk will provide an overview of the current state of knowledge on the effects of psychedelic substances on the brain and their potential relation to treatment efficacy. It will furthermore discuss how elucidating the clinical mechanisms of action can help advancing psychedelic-assisted therapy.
Katrin Preller, received her M.Sc. (Neuropsychology) from University of Konstanz, Germany. For her PhD she went to University of Zurich, Switzerland, where she investigated the neurobiological and social-cognitive long-term effects of cocaine, MDMA, and heroin use. After completing her PhD, she joined the Neuropsychopharmacology and Brain Imaging lab at the Psychiatric University Hospital Zurich, investigating the effects of psilocybin and LSD on self-perception, social cognition, and multimodal processing using different brain imaging techniques. She furthermore worked as Postdoc at the Wellcome Trust Centre for Neuroimaging, UCL, London, UK, and Yale University, New Haven, CT, USA and is currently investigating the neurobiology of psychedelics in clinical and pre-clinical studies.